Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

August 2018

Voluntary Home Infusion Program for Remicade and IVIG


Beginning on Sept. 1, Harvard Pilgrim will be offering a voluntary home infusion program for infliximab and immunoglobulin (IVIG) treatment in conjunction with Coram CVS Specialty Infusion Services. If any of your Harvard Pilgrim members are administered these medications in an outpatient setting, you and the patient may receive a letter or phone call from a CVS/Coram clinical care team member to discuss the possibility of having the patient receive home infusion services.

Since many patients prefer receiving infusion services in the comfort of their home, this voluntary program offers our members added convenience, and is cost-effective.

The medical drugs included in this voluntary program are:

  • Infliximab — Remicade, Inflectra, Renflexis
  • IVIG — Bivigam, Carimune, Flebogamma, Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, and Privigen.

How the program works

CVS/Coram will contact patients receiving these medications to determine if they are interested in home infusion services. If so, the CVS/Coram clinical staff will contact the physician to review the member’s case and ensure that the patient is an appropriate candidate for in-home service. If the provider agrees, Coram will collaborate with the provider on the transition to home infusion, working together to obtain the necessary orders and making the therapy arrangements with the patient.

At the start of the program, a CVS/Coram care team member will perform a detailed initial clinical assessment for the medication and an introduction to Coram with the patient. The same nurse will be assigned for each visit with the patient; this consistency helps ensure that subtle changes in patient response to treatment can be identified over time. After each visit, Coram will provide the patient’s physician with a clinical report via fax or telephone, based on the physician’s preference.

Other home infusion providers may be used

While we are working with CVS/Coram on outreach for this voluntary program, you may choose to use another home infusion provider. If you currently work with a home infusion provider for these or other medications, you can continue to do so. If you want to get a patient started with home infusion but would prefer to use a vendor other than Coram, contact Harvard Pilgrim’s Provider Service Center at 800-708-4414.

Prior authorization needed

Information about the program will be included in authorization determination letters after prior authorization has been granted, and phone calls to the member and physician will occur after that. We will also send letters about this home infusion program to providers with patients who were authorized to receive these intravenous medications earlier in 2018, as well as to these patients.

As a reminder, the medical drugs included in this program require prior authorization from CVS Health—Novologix. For details on the prior authorization program for medical drugs, including criteria and prior authorization request forms, please refer to the Medical Drug Prior Authorization page on our provider website.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

New Partnership Leverages Digital Tech for Care Management

Voluntary Home Infusion Program for Remicade and IVIG

CLINICIAN CORNER

Promote the Flu Vaccine to Your Patients for the Upcoming Season

New HCPCS Codes for Hemlibra and Luxturna

Opdivo Approved for an Additional Indication

Rebinyn and Durolane to be Covered with Prior Authorization

Prior Authorization No Longer Required for Cologuard Test

Members’ Rights and Responsibilities

Pharmacy & Therapeutics Committee Meeting Update

Recognizing Generalized Anxiety Disorder in the Primary Care Setting

OFFICE ASSISTANT

Home Care Providers: Billing for Postnatal Skilled Nursing Home Visits

270/271 Eligibility Response Update and Telemedicine Billing Reminders

Billing for Facility-Based Urgent Care

QMB Members Cannot be Billed for Medicare Parts A and B Cost-Sharing

PUBLICATION INFORMATION

Robert Farias,
Senior Vice President, Corporate Network Strategy

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator